Radiologic Predictors of Disease Recurrence in Nasopharyngeal Carcinoma: A Retrospective Evaluation of MRI and (18)F-FDG-PET/CT Parameters

鼻咽癌疾病复发的放射学预测因子:MRI 和 (18)F-FDG-PET/CT 参数的回顾性评估

阅读:1

Abstract

Background/Objectives: NPC is a radiosensitive malignancy with high recurrence rates despite therapeutic advances. This study aimed to identify radiologic and metabolic predictors of recurrence in newly diagnosed NPC by integrating MRI and (18)F-FDG PET/CT parameters. Methods: Fifty-two patients with biopsy-proven, previously untreated NPC who underwent pre-treatment MRI and (18)F-FDG PET/CT were retrospectively analyzed. Local tumor features, nodal status, and response patterns were evaluated using MRI and PET/CT-derived metrics: SUVmax, SUVmean, SUVpeak, MTV, and TLG. The post-treatment MRI response was categorized into six patterns. Univariate and multivariate analyses were performed to identify independent predictors. Results: Recurrence occurred in 27% of patients. Based on the multivariate analysis, PNI, extensive PPS invasion, GTV, and metastatic LN count were identified as independent predictors of recurrence (PNI: OR = 1.60, p = 0.029; PPS: OR = 1.23, p = 0.027; GTV: OR = 1.08, p = 0.042; LN count: OR = 1.20, p = 0.031). PNI and PPS invasion were significantly associated with local failure (HR = 8.21, p = 0.008 and HR = 3.52, p = 0.043, respectively). GTV was independently associated with an increased risk of local (HR = 1.14, p = 0.021) and distant recurrence (HR = 1.19, p = 0.024). The presence of metastatic disease at diagnosis (HR = 6.27, p = 0.027) and a higher LN count (HR = 1.17, p = 0.028) were also linked to distant failure. Conclusions: Imaging-derived predictors including GTV, PNI, LN burden, and MRI-based response patterns demonstrate prognostic value for disease recurrence in NPC and may guide risk-adapted treatment strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。